



Date of report 13 May 2019

## Reported case interaction between **Cobicistat** and **Alprazolam**

### Drugs suspected to be involved in the DDI

Perpetrator

**Cobicistat**

Daily Dose

150 (mg)

Dose adjustment performed

No

Administration Route

Oral

Start date

Unknown

End date

Ongoing

Victim

**Alprazolam**

Daily Dose

0.75 (mg)

Dose adjustment performed

No

Administration Route

Oral

Start date

Unknown

End date

Ongoing

## Complete list of drugs taken by the patient

Antiretroviral treatment

Darunavir/Cobicistat

Raltegravir

Lamivudine

Complete list of all comedications taken by the patient, included that involved in the DDI

alprazolam, escitalopram, ipratropium bromide, salbutamol

## Clinical case description

Gender

Female

Age

56

eGFR (mL/min)

>60

Liver function impairment

No

Description

Female patient with potential DDI between DRV/c and alprazolam. No toxicity was observed

## Clinical Outcome

**No unwanted outcome**

## Editorial Comment

Coadministration has not been studied. Alprazolam is mainly metabolized by CYP3A4. Coadministration of darunavir/

cobicistat may increase alprazolam concentrations and may result in enhanced sedation. A decrease in alprazolam dose may be needed.

## University of Liverpool Recommendation

- Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration

For more information [click here](#)